Showing results (31-40 of 240) with videos related to
Sort By:
Pageof 24
Oncotarget|January 14, 2016
MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantationLuciana De Luca, Stefania Trino, Ilaria Laurenzana, et al.International Journal of Molecular Sciences|March 14, 2026
Clonal Dynamics of FLT3-ITD from Diagnosis to Relapse: Ultra-Sensitive Patient-Specific Monitoring by ddPCRAlessandro Ferrando, Johanna Umurungi, Alice Costanza Danzero, et al.Haematologica|April 12, 2005
New tyrosine kinase inhibitors in chronic myeloid leukemiaGiovanni Martinelli, Simona Soverini, Gianantonio Rosti, et al.Haematologica|August 2, 2007
Nuclear factor kB as a target for new drug development in myeloid malignanciesDaniela Cilloni, Giovanni Martinelli, Francesca Messa, et al.Biomarker Research|July 7, 2015
Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISHValentina Rosso, Enrico Bracco, Roberto Pedrola, et al.Journal of Clinical Medicine|February 15, 2022
Revealing the Mysteries of Acute Myeloid Leukemia: From Quantitative PCR through Next-Generation Sequencing and Systemic Metabolomic ProfilingCristina Panuzzo, Aleksandar Jovanovski, Muhammad Shahzad Ali, et al.Leukemia & Lymphoma|April 10, 2008
New therapeutic approaches and prognostic factors in chronic myeloid leukemiaGiuseppe Saglio, Stefano Ulisciani, Marco Bosa, et al.Expert Opinion on Biological Therapy|December 24, 2005
Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotectionAntonio Uccelli, Emanuela Zappia, Federica Benvenuto, et al.Haematologica|November 21, 2007
Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phaseFrancesca Palandri, Ilaria Iacobucci, Fabrizio Quarantelli, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patientsIlaria Iacobucci, Giuseppe Saglio, Gianantonio Rosti, et al.Pageof 24